» Articles » PMID: 12897217

Acute and Chronic Arsenic Toxicity

Overview
Journal Postgrad Med J
Specialty General Medicine
Date 2003 Aug 5
PMID 12897217
Citations 235
Authors
Affiliations
Soon will be listed here.
Abstract

Arsenic toxicity is a global health problem affecting many millions of people. Contamination is caused by arsenic from natural geological sources leaching into aquifers, contaminating drinking water and may also occur from mining and other industrial processes. Arsenic is present as a contaminant in many traditional remedies. Arsenic trioxide is now used to treat acute promyelocytic leukaemia. Absorption occurs predominantly from ingestion from the small intestine, though minimal absorption occurs from skin contact and inhalation. Arsenic exerts its toxicity by inactivating up to 200 enzymes, especially those involved in cellular energy pathways and DNA synthesis and repair. Acute arsenic poisoning is associated initially with nausea, vomiting, abdominal pain, and severe diarrhoea. Encephalopathy and peripheral neuropathy are reported. Chronic arsenic toxicity results in multisystem disease. Arsenic is a well documented human carcinogen affecting numerous organs. There are no evidence based treatment regimens to treat chronic arsenic poisoning but antioxidants have been advocated, though benefit is not proven. The focus of management is to reduce arsenic ingestion from drinking water and there is increasing emphasis on using alternative supplies of water.

Citing Articles

Recent advances in the clinical management of intoxication by five heavy metals: Mercury, lead, chromium, cadmium and arsenic.

Balali-Mood M, Eizadi-Mood N, Hassanian-Moghaddam H, Etemad L, Moshiri M, Vahabzadeh M Heliyon. 2025; 11(4):e42696.

PMID: 40040983 PMC: 11876891. DOI: 10.1016/j.heliyon.2025.e42696.


Potential Health Impacts, Treatments, and Countermeasures of Martian Dust on Future Human Space Exploration.

Wang J, Rosenbaum J, Prasad A, Raad R, Putman E, Harrington A Geohealth. 2025; 9(2):e2024GH001213.

PMID: 39944899 PMC: 11815326. DOI: 10.1029/2024GH001213.


Molecular evidence of the inhibitory potential of melatonin against sodium arsenite toxicity.

Farhadi R, Daniali M, Baeeri M, Khorasani R, Haghi-Aminjan H, Gholami M Heliyon. 2025; 11(3):e42113.

PMID: 39916822 PMC: 11799970. DOI: 10.1016/j.heliyon.2025.e42113.


Heritable dysregulation of DNA methylation may underlie the diabetogenic effects of paternal preconception exposure to inorganic arsenic in C57BL/6J mice.

Hartwell H, Shang B, Douillet C, Bousquet A, Liu T, Zou F Toxicol Appl Pharmacol. 2025; 496:117242.

PMID: 39894169 PMC: 11846692. DOI: 10.1016/j.taap.2025.117242.


Engineering human cerebral organoids to explore mechanisms of arsenic-induced developmental neurotoxicity.

Wu X, Kreutz A, Dixon D, Tokar E Toxicol Appl Pharmacol. 2025; 496:117230.

PMID: 39842615 PMC: 11846691. DOI: 10.1016/j.taap.2025.117230.


References
1.
Buchet J, Lison D, Ruggeri M, Foa V, Elia G . Assessment of exposure to inorganic arsenic, a human carcinogen, due to the consumption of seafood. Arch Toxicol. 1996; 70(11):773-8. DOI: 10.1007/s002040050339. View

2.
Shen Z, Chen G, Ni J, Li X, Xiong S, Qiu Q . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89(9):3354-60. View

3.
APOSHIAN H . Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol. 1997; 37:397-419. DOI: 10.1146/annurev.pharmtox.37.1.397. View

4.
Guo H, Chiang H, Hu H, Lipsitz S, Monson R . Arsenic in drinking water and incidence of urinary cancers. Epidemiology. 1997; 8(5):545-50. DOI: 10.1097/00001648-199709000-00012. View

5.
Chiou H, HUANG W, Su C, Chang S, Hsu Y, Chen C . Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke. 1997; 28(9):1717-23. DOI: 10.1161/01.str.28.9.1717. View